Natural killer-dendritic cell cross-talk in cancer immunotherapy

Expert Opinion on Biological Therapy

Volumn 5, Issue 10, 2005, Pages 1303-1315

  Kalinski, Pawel ^a,b,c   Mailliard, Robbie B ^b   Giermasz, Adam ^b   Zeh, Herbert J ^a   Basse, Per ^a   Bartlett, David L ^a,b   Kirkwood, John M ^a,b   Lotze, Michael T ^b,d   Herberman, Ronald B ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d Molecular Medicine Institute   (United States)

Author keywords

Cancer; Clinical trials; Colorectal cancer; CTL; Dendritic cells; HIV; Immunotherapy; Melanoma; NK cells; Th1; Vaccines

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL INTERACTION; CELL MATURATION; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; HELPER CELL; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MELANOMA; MOLECULAR RECOGNITION; NATURAL KILLER CELL; NONHUMAN; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION;

ANIMALS; CELL COMMUNICATION; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; NEOPLASMS; RECEPTOR CROSS-TALK; RECEPTORS, IMMUNOLOGIC;

EID: 27144538614     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.10.1303     Document Type: Review

References (151)

1. BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392(6673):245-252.
2. SCHULER G, SCHULER-THURNER B, STEINMAN RM: The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. (2003) 15(2):138-147.
3. SCHULER G, STEINMAN RM: Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. (1997) 186(8):1183-1187.
4. KALINSKI P, HILKENS CM, WIERENGA EA, KAPSENBERG ML: T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today (1999) 20(12):561-567.
5. KAPSENBERG ML: Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. (2003) 3(12):984-993.
6. IKEDA H, CHAMOTO K, TSUJI T et al.: The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. (2004) 95(9):697-703.
7. PULENDRAN B: Modulating TH1/TH2 responses with microbes, dendritic cells, and pathogen recognition receptors. Immunol. Res. (2004) 29(1-3):187-196.
8. TRINCHIERI G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. (2003) 3(2):133-146.
9. PALUCKA K, BANCHEREAU J: How dendritic cells and microbes interact to elicit or subvert protective immune responses. Curr. Opin. Immunol. (2002) 14(4):420-431.
10. CZERNIECKI BJ, COHEN PA, FARIES M et al.: Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines. Crit. Rev. Immunol. (2001) 21(1-3):157-178.
11. KALINSKI P, MOSER M: Consensual immunity: success-driven development of T-helper-1 and T-helper-2 responses. Nat. Rev. Immunol. (2005) 5(3):251-260.
12. MORA JR, BONO MR, MANJUNATH N et al.: Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature (2003) 424(6944):88-93.
13. MORA JR, CHENG G, PICARELLA D et al.: Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues. J. Exp. Med. (2005) 201(2):303-316.
14. MORA JR, VON ANDRIAN UH: Retinoic acid: an educational 'vitamin elixir' for gut-seeking T cells. Immunity (2004) 21(4):458-460.
15. SCHAERLI P, LOETSCHER P, MOSER B: Cutting edge: induction of follicular homing precedes effector Th cell development. J. Immunol. (2001) 167(11):6082-6086.
16. STAGG AJ, KAMM MA, KNIGHT SC: Intestinal dendritic cells increase T cell expression of alpha4beta7 integrin. Eur. J. Immunol. (2002) 32(5):1445-l454.
17. WENINGER W, MANJUNATH N, VON ANDRIAN UH: Migration and differentiation of CD8+ T cells. Immunol. Rev. (2002) 186:221-233.
18. CALZASCIA T, MASSON F, DI BERARDINO-BESSON W et al.: Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity (2005) 22(2):175-184.
19. FERNANDEZ NC, LOZIER A, FLAMENT C et al.: Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. (1999) 5(4):405-411.
20. FERLAZZO G, TSANG ML, MORETTA L et al.: Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. (2002) 195(3):343-351.
21. GEROSA F, BALDANI-GUERRA B, NISII C et al.: Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. (2002) 195(3):327-333.
22. PICCIOLI D, SBRANA S, MELANDRI E, VALIANTE NM: Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. (2002) 195(3):335-341.
23. PULENDRAN B, PALUCKA K, BANCHEREAU J: Sensing pathogens and tuning immune responses. Science (2001) 293(5528):253-256.
24. MOSER M, MURPHY KM: Dendritic cell regulation of TH1-TH2 development. Nat. Immunol. (2000) 1(3):199-205.
25. LIU YJ, KANZLER H, SOUMELIS V, GILLIET M: Dendritic cell lineage, plasticity and cross-regulation. Nat. Immunol. (2001) 2(7):585-589.
26. JANEWAY CA JR, MEDZHITOV R: Innate immune recognition. Annu. Rev. Immunol. (2002) 20:197-216.
27. MATZINGER P: Tolerance, danger, and the extended family. Annu. Rev. Immunol. (1994) 12:991-1045.
28. ACKERMAN AL, CRESSWELL P: Regulation of MHC class I transport in human dendritic cells and the dendritic-like cell line KG-1. J. Immunol. (2003) 170(8):4178-4188.
29. GROHMANN U, BELLADONNA ML, BIANCHI R et al.: Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex. Cancer Immunol. Immunother. (1999) 48(4):195-203.
30. KUCHTEY J, PENNINI M, PAI RK, HARDING CV: CpG DNA induces a class II transactivator-independent increase in class II MHC by stabilizing class II MHC mRNA in B lymphocytes. J. Immunol. (2003) 171(5):2320-2325.
31. KUKUTSCH NA, ROSSNER S, AUSTYN JM, SCHULER G, LUTZ MB: Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells. J. Invest. Dermatol. (2000) 115(3):449-453.
32. FIEBIGER E, MERANER P, WEBER E et al.: Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen presentation by dendritic cells. J. Exp. Med. (2001) 193(8):881-892.
33. PAI RK, ASKEW D, BOOM WH, HARDING CV: Regulation of class II MHC expression in APCs: roles of types I, III, and IV class II transactivator. J. Immunol. (2002) 169(3):1326-1333.
34. VEERASWAMY RK, CELLA M, COLONNA M, UNANUE ER: Dendritic cells process and present antigens across a range of maturation states. J. Immunol. (2003) 170(11):5367-5372.
35. KALINSKI P, SCHUITEMAKER JH, HILKENS CM, WIERENGA EA, KAPSENBERG ML: Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J. Immunol. (1999) 162(6):3231-3236.
36. LANGENKAMP A, MESSI M, LANZAVECCHIA A, SALLUSTO F: Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat. Immunol. (2000) 1(4):311-316.
37. GROUARD G, RISSOAN MC, FILGUEIRA L et al.: The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J. Exp. Med. (1997) 185(6):1101-1111.
38. KADOWAKI N, LIU YJ: Natural Type I interferon-producing cells as a link between innate and adaptive immunity. Hum. Immunol. (2002) 63(12):1126-1132.
39. LIU YJ: IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. (2005) 23:275-306.
40. RISSOAN MC, SOUMELIS V, KADOWAKI N et al.: Reciprocal control of T helper cell and dendritic cell differentiation. Science (1999) 283(5405):1183-1186.
41. COLONNA M, KRUG A, CELLA M: Interferon-producing cells: on the front line in immune responses against pathogens. Curr. Opin. Immunol. (2002) 14(3):373-379.
42. SANDBERG K, MATSSON P, ALM GV: A distinct population of nonphagocytic and low level CD4+ null lymphocytes produce IFN-alpha after stimulation by herpes simplex virus-infected cells. J. Immunol. (1990) 145(3):1015-1020.
43. CEDERBLAD B, ALM GV: Infrequent but efficient interferon-alpha-producing human mononuclear leukocytes induced by herpes simplex virus in vitro studied by immunoplaque and limiting dilution assays. J. Interferon Res. (1990) 10(1):65-73.
44. RONNBLOM L, RAMSTEDT U, ALM GV: Properties of human natural interferon-producing cells stimulated by tumor cell lines. Eur. J. Immunol. (1983) 13(6):471-476.
45. PALAMARA F, MEINDL S, HOLCMANN M et al.: Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J. Immunol. (2004) 173(5):3051-3061.
46. HARTMANN E, WOLLENBERG B, ROTHENFUSSER S et al.: Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. (2003) 63(19):6478-6487.
47. SCHNURR M, TOY T, SHIN A et al.: Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood (2004) 103(4):1391-1397.
48. LIU YJ: IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell Precursors. Annu. Rev. Immunol. (2005) 23:275-306.
49. MONTOYA M, EDWARDS MJ, REID DM, BORROW P: Rapid activation of spleen dendritic cell subsets following lymphocytic choriomeningitis virus infection of mice: analysis of the involvement of Type 1 IFN. J. Immunol. (2005) 174(4):1851-1861.
50. ITO T, WANG YH, LIU YJ: Plasmacytoid dendritic cell precursors/type I interferon-producing cells sense viral infection by Toll-like receptor (TLR) 7 and TLR9. Springer Semin. Immunopathol. (2005) 26(3):221-229.
51. AZZONI L, RUTSTEIN RM, CHEHIMI J et al.: Dendritic and natural killer cell subsets associated with Stable or declining CD4+ cell counts in treated HIV/-1-infected children. J. Infect. Dis. (2005) 191(9):1451-1459.
52. MEGJUGORAC NJ, YOUNG HA, AMRUTE SB, OLSHALSKY SL, FITZGERALD-BOCARSLY P: Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. J. Leukoc. Biol. (2004) 75(3):504-514.
53. KANTO T, INOUE M, MIYATAKE H et al.: Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. J. Infect. Dis. (2004) 190(11):1919-1926.
54. FINKE JS, SHODELL M, SHAH K, SIEGAL FP, STEINMAN RM: Dendritic cell numbers in the blood of HIV-1 infected patients before and after changes in antiretroviral therapy. J. Clin. Immunol. (2004) 24(6):647-652.
55. DUAN XZ, WANG M, LI HW et al.: Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans. J. Clin. Immunol. (2004) 24(6):637-646.
56. DALLOUL A, OKSENHENDLER E, CHOSIDOW O et al.: Severe herpes virus (HSV-2) infection in two patients with myelodysplasia and undetectable NK cells and plasmacytoid dendritic cells in the blood. J. Clin. Virol. (2004) 30(4):329-336.
57. BJORCK P: Dendritic cells exposed to herpes simplex virus in vivo do not produce IFN-alpha after rechallenge with virus in vitro and exhibit decreased T cell alloreactivity. J. Immunol. (2004) 172(9): 5396-5404.
58. DALOD M, HAMILTON T, SALOMON R et al.: Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta. J. Exp. Med. (2003) 197(7):885-898.
59. GEROSA F, GOBBI A, ZORZI P et al.: The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J. Immunol. (2005) 174(2):727-734.
60. MUNN DH, SHARMA MD, HOU D et al.: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. (2004) 114(2):280-290.
61. FALLARINO F, ASSELIN-PATUREL C, VACCA C et al.: Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J. Immunol. (2004) 173(6):3748-3754.
62. MASON KA, ARIGA H, NEAL R et al.: Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin. Cancer Res. (2005) 11(1):361-369.
63. KRIEG AM, EFLER SM, WITTPOTH M, AL ADHAMI MJ, DAVIS HL: Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother. (2004) 27(6):460-471.
64. KRIEG AM: Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr. Oncol. Rep. (2004) 6(2):88-95.
65. DHODAPKAR MV, STEINMAN RM, SAPP M et al.: Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. (1999) 104(2):173-180.
66. DE VRIES IJ, LESTERHUIS WJ, SCHARENBORG NM et al.: Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res. (2003) 9(14):5091-5100.
67. ADEMA GJ, DE VRIES IJ, PUNT CJ, FIGDOR CG: Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr. Opin. Immunol. (2005) 17(2):170-174.
68. DE VRIES IJ, KROOSHOOP DJ, SCHARENBORG NM et al.: Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. (2003) 63(1):12-17.
69. MOSER B, LOETSCHER P: Lymphocyte traffic control by chemokines. Nat. Immunol. (2001) 2(2):123-128.
70. CAMPBELL DJ, KIM CH, BUTCHER EC: Chemokines in the systemic organization of immunity. Immunol. Rev. (2003) 195:58-71.
71. NIBBS R, GRAHAM G, ROT A: Chemokines on the move: control by the chemokine 'interceptors' Duffy blood group antigen and D6. Semin. Immunol. (2003) 15(5):287-294.
72. MANTOVANI A, ALLAVENA P, SOZZANI S et al.: Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin. Cancer Biol. (2004) 14(3):155-160.
73. MOSER B, WOLF M, WALZ A, LOETSCHER P: Chemokines: multiple levels of leukocyte migration control. Trends Immunol. (2004) 25(2):75-84.
74. ROT A, VON ANDRIAN UH: Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. (2004) 22:891-928.
75. ZITVOGEL L, MAYORDOMO JI, TJANDRAWAN T et al.: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. (1996) 183(1):87-97.
76. ZITVOGEL L, ROBBINS PD, STORKUS WJ et al.: Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol. (1996) 26(6):1335-1341.
77. FURUMOTO K, ARII S, YAMASAKI S et al.: Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses. Int. J. Cancer (2000) 87(5):665-672.
78. FURUMOTO K, MORI A, YAMASAKI S et al.: Interleukin-12-gene transduction makes DCs from tumor-bearing mice an effective inducer of tumor-specific immunity in a peritoneal dissemination model. Immunol. Lett. (2002) 83(1):13-20.
79. NISHIOKA Y, HIRAO M, ROBBINS PD, LOTZE MT, TAHARA H: Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. (1999) 59(16):4035-4041.
80. OKADA N, IIYAMA S, OKADA Y et al.: Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. Cancer Gene Ther. (2005) 12(1):72-83.
81. REDLINGER RE JR, MAILLIARD RB, BARKSDALE EM JR: Advanced neuroblastoma impairs dendritic cell function in adoptive immunotherapy. J. Pediatr. Surg. (2003) 38(6):857-862.
82. SATOH Y, ESCHE C, GAMBOTTO A et al.: Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J. Exp. Ther. Oncol. (2002) 2(6):337-349.
83. SHIMIZU T, BERHANU A, REDLINGER RE JR et al.: Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma. J. Pediatr. Surg. (2001) 36(8):1285-1292.
84. YAMANAKA R, ZULLO SA, RAMSEY J et al.: Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J. Neurosurg. (2002) 97(3):611-618.
85. ZHANG S, ZENG G, WILKES DS et al.: Dendritic cells transfected with interleukin-12 and pulsed with tumor extract inhibit growth of murine prostatic carcinoma in vivo. Prostate (2003) 55(4):292-298.
86. JONULEIT H, KUHN U, MULLER G et al.: Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. (1997) 27(12):3135-3142.
87. MAILLIARD RB, WANKOWICZ-KALINSKA A, CAI Q et al.: alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. (2004) 64(17):5934-5937.
88. LUFT T, JEFFORD M, LUETJENS P et al.: Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood (2002) 100(4):1362-1372.
89. SCANDELLA E, MEN Y, GILLESSEN S, FORSTER R, GROETTRUP M: Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood (2002) 100(4):1354-1361.
90. VIEIRA PL, DE JONG EC, WIERENGA EA, KAPSENBERG ML, KALINSKI P: Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J. Immunol. (2000) 164(9):4507-4512.
91. HERBERMAN RB, DJEU J, KAY HD et al.: Natural killer cells: characteristics and regulation of activity. Immunol. Rev. (1979) 44:43-70.
92. BONDESTAM M, FUNA K, ALM GV: Defective leukocyte interferon response in children with recurrent infections accompanied by arthralgia. Acta Paediatr. Scand. (1985) 74(2):219-225.
93. FLEISHER G, STARR S, KOVEN N et al.: A non-x-linked syndrome with susceptibility to severe Epstein-Barr virus infections. J. Pediatr. (1982) 100(5):727-730.
94. FUJIMIYA Y, BABIUK LA, ROUSE BT: Direct lymphocytotoxicity against herpes simplex virus infected cells. Can. J. Microbiol. (1978) 24(9):1076-1081.
95. BIRON CA, BYRON KS, SULLIVAN JL: Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. (1989) 320(26):1731-1735.
96. MAILLIARD RB, SON YI, REDLINGER R et al.: Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J. Immunol. (2003) 171(5):2366-2373.
97. KIESSLING R, WIGZELL H: An analysis of the murine NK cell as to structure, function and biological relevance. Immunol. Rev. (1979) 44:165-208.
98. TIMONEN T, ORTALDO JR, HERBERMAN RB: Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J. Exp. Med. (1981) 153(3):569-582.
99. MORETTA A: Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat. Rev. Immunol. (2002) 2(12):957-964.
100. MORETTA L, BIASSONI R, BOTTINO C et al.: Human NK cells and their receptors. Microbes Infect. (2002) 4(15):1539-1544.
101. MCQUEEN KL, PARHAM P: Variable receptors controlling activation and inhibition of NK cells. Curr. Opin. Immunol. (2002) 14(5):615-621.
102. KARRE K: NK cells, MHC class I molecules and the missing self. Scand. J. Immunol. (2002) 55(3):221-228.
103. RYAN JC, NAPER C, HAYASHI S, DAWS MR: Physiologic functions of activating natural killer (NK) complex-encoded receptors on NK cells. Immunol. Rev. (2001) 181:126-137.
104. TOMASELLO E, BLERY M, VELY F, VIVIER E: Signaling pathways engaged by NK cell receptors: double concerto for activating receptors, inhibitory receptors and NK cells. Semin. Immunol. (2000) 12(2):139-147.
105. MORETTA A, BIASSONI R, BOTTINO C, MORETTA L: Surface receptors delivering opposite signals regulate the function of human NK cells. Semin. Immunol. (2000) 12(2):129-138.
106. COLONNA M, NAKAJIMA H, CELLA M: Inhibitory and activating receptors involved in immune surveillance by human NK and myeloid cells. J. Leukoc. Biol. (1999) 66(5):718-722.
107. VIVIER E, NUNES JA, VELY F: Natural killer cell signaling pathways. Science (2004) 306(5701):1517-1519.
108. VIVIER E, ANFOSSI N: Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat. Rev. Immunol. (2004) 4(3):190-198.
109. NO AUTHORS LISTED: Prostate cancer vaccine-Northwest Biotherapeutics: CaPVax, DC1/HRPC, DCVax-Prostate. BioDrugs (2002) 16(3):226-227.
110. BIRON CA, BROSSAY L: NK cells and NKT cells in innate defense against viral infections. Curr. Opin. Immunol. (2001) 13(4):458-464.
111. BIRON CA, NGUYEN KB, PIEN GC: Innate immune responses to LCMV infections: natural killer cells and cytokines. Curr. Top. Microbiol. Immunol. (2002) 263:7-27.
112. DIEFENBACH A, TOMASELLO E, LUCAS M et al.: Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat. Immunol. (2002) 3(12):1142-1149.
113. JINUSHI M, TAKEHARA T, TATSUMI T et al.: Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J. Immunol. (2004) 173(10):6072-6081.
114. CASTRICONI R, DELLA CHIESA M, MORETTA A: Shaping of adaptive immunity by innate interactions. C. R. Biol. (2004) 327(6):533-537.
115. PIETRA G, ROMAGNANI C, MAZZARINO P et al.: Comparative analysis of NK- or NK-CTL-mediated lysis of immature or mature autologous dendritic cells. Eur. J. Immunol. (2003) 33(12):3427-3432.
116. DELLA CHIESA M, VITALE M, CARLOMAGNO S et al.: The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur. J. Immunol. (2003) 33(6):1657-1666.
117. DOHERTY PC, ALLAN JE: Anti-asialo GM1 eliminates both inflammatory process and cytotoxic T-cell function in the lymphocytic choriomeningitis adoptive transfer model. Cell. Immunol. (1987) 107(1):1-7.
118. KELLY JM, DARCY PK, MARKBY JL et al.: Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. (2002) 3(1):83-90.
119. KELLY JM, TAKEDA K, DARCY PK, YAGITA H, SMYTH MJ: A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo. J. Immunol. (2002) 168(9):4472-4479.
120. COUDERT JD, COUREAU C, GUERY JC: Preventing NK cell activation by donor dendritic cells enhances allospecific CD4 T cell priming and promotes Th Type 2 responses to transplantation antigens. J. Immunol. (2002) 169(6):2979-2987.
121. SZOMOLANYI-TSUDA E, BRIEN JD, DORGAN JE et al.: Antiviral T-cell-independent Type 2 antibody responses induced in vivo in the absence of T and NK cells. Virology (2001) 280(2):160-168.
122. HUSSELL T, OPENSHAW PJ: IL-12-activated NK cells reduce lung eosinophilia to the attachment protein of respiratory syncytial virus but do not enhance the severity of illness in CD8 T cell-immunodeficient conditions. J. Immunol. (2000) 165(12):7109-7115.
123. MOCIKAT R, BRAUMULLER H, GUMY A et al.: Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity (2003) 19(4):561-569.
124. MARTIN-FONTECHA A, THOMSEN LL, BRETT S et al.: Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat. Immunol. (2004) 5(12):1260-1265.
125. DIEFENBACH A, RAULET DH: The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol. Rev. (2002) 188:9-21.
126. FERLAZZO G, MORANDI B, D'AGOSTINO A et al.: The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur. J. Immunol. (2003) 33(2):306-313.
127. VITALE M, CHIESA MD, CARLOMAGNO S et al.: NK-dependent DC maturation is mediated by TNF{alpha} and IFN{gamma} released upon engagement of the NKp30 triggering receptor. Blood (2005) 106(2):566-571.
128. KAMATH AT, SHEASBY CE, TOUGH DF: Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-{alpha}{beta} and IFN-{gamma}. J. Immunol. (2005) 174(2):767-776.
129. REYNOLDS CW, TIMONEN T, HERBERMAN RB: Natural killer (NK) cell activity in the rat. I. Isolation and characterization of the effector cells. J. Immunol. (1981) 127(1):282-287.
130. FERLAZZO G, PACK M, THOMAS D et al.: Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl. Acad. Sci. USA (2004) 101(47):16606-16611.
131. COOPER MA, FEHNIGER TA, TURNER SC et al.: Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood (2001) 97(10):3146-3151.
132. FEHNIGER TA, COOPER MA, NUOVO GJ et al.: CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood (2003) 101(8):3052-3057.
133. FERLAZZO G, THOMAS D, LIN SL et al.: The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J. Immunol. (2004) 172(3):1455-1462.
134. CARSON WE, FEHNIGER TA, CALIGIURI MA: CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur. J. Immunol. (1997) 27(2):354-360.
135. SOTO H, WANG W, STRIETER RM et al.: The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. Proc. Natl. Acad. Sci. USA (1998) 95(14):8205-8210.
136. WANG X, LI X, SCHMIDT DB et al.: Identification and molecular characterization of rat CXCR3: receptor expression and interferon-inducible protein-10 binding are increased in focal stroke. Mol. Pharmacol. (2000) 57(6):1190-1198.
137. JENH CH, COX MA, KAMINSKI H et al.: Cutting edge: species specificity of the CC chemokine 6Ckine signaling through the CXC chemokine receptor CXCR3: human 6Ckine is not a ligand for the human or mouse CXCR3 receptors. J. Immunol. (1999) 162(7):3765-3769.
138. FREUD AG BB, ROYCHOWDHURY S, MAO HC et al.: A human CD34(+) subset resides in lymph nodes and differentiates into CD56(bright) natural killer cells. Immunity (2005) 22(3):295-304.
139. ALBERT ML, SAUTER B, BHARDWAJ N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 392(6671):86-89.
140. LOTZE MT, DEMARCO RA: Dealing with death: HMGB1 as a novel target for cancer therapy. Curr. Opin. Investig. Drugs (2003) 4(12):1405-1409.
141. VAKKILA J, LOTZE MT: Inflammation and necrosis promote tumour growth. Nat. Rev. Immunol. (2004) 4(8):641-648.
142. LOTZE MT, TRACEY KJ: High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. (2005) 5(4):331-342.
143. TSUNG A, SAHAI R, TANAKA H et al.: The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. (2005) 201(7):1135-1143.
144. ZEH HJ 3RD, LOTZE MT: Addicted to death: invasive cancer and the immune response to unscheduled cell death. J. Immunother. (2005) 28(1):1-9.
145. KALINSKI P, SCHUITEMAKER JH, HILKENS CM, KAPSENBERG ML: Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J. Immunol. (1998) 161(6):2804-2809.
146. KALINSKI P, SMITS HH, SCHUITEMAKER JH et al.: IL-4 is a mediator of IL-12p70 induction by human Th2 cells: reversal of polarized Th2 phenotype by dendritic cells. J. Immunol. (2000) 165(4):1877-1881.
147. ENGLEMAN EG: Dendritic cell-based cancer immunotherapy. Semin. Oncol. (2003) 30(3 Suppl. 8):23-29.
148. BASSE PH, WHITESIDE TL, CHAMBERS W, HERBERMAN RB: Therapeutic activity of NK cells against tumors. Int. Rev. Immunol. (2001) 20(3-4):439-501.
149. ROSENBERG SA, YANG JC, RESTIFO NP: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. (2004) 10(9):909-915.
150. COSTELLO RT, SIVORI S, MARCENARO E et al.: Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood (2002) 99(10):3661-3667.
151. FAURIAT C, MORETTA A, OLIVE D, COSTELLO RT: Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients. Blood (2005) 106(6):2186-2188.